All sponsors

Nanjing Leads Biolabs Co.,Ltd

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS12
PHASE 3 / 2-31
RECRUITING11
READOUTS ≤12 MONTHS4
READOUT SLIPPED >6 MO43%

Delay Index: of 7 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +1.2 months). See all sponsors →

Open Nanjing Leads Biolabs Co.,Ltd on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
LBL-024 for Injection
NCT05170958
P1/2RecruitingAdvanced Solid Tumor3962026-12 (+29 mo)
LBL-024 for Injection
NCT06783647
P2RecruitingAdvanced Solid Tumour2502026-12-24
LBL-024 for Injection
NCT06157827
P1/2RecruitingAdvanced Neuroendocrine Carcinoma1782026-12-28 (+1 mo)
LBL-024 for Injection
NCT07099430
P1/2RecruitingAdvanced Melanoma2802027-10-30
LBL-024 for Injection
NCT07042802
P1/2RecruitingOvarian Cancer1802027-12-25
LBL-024 for Injection
NCT07111546
P2RecruitingAdvanced Solid Tumour1402027-12-26 (+12 mo)
LBL-024 for Injection
NCT07281976
P1/2RecruitingTriple Negative Breast Cancer2202027-12-31
LBL-024 for Injection
NCT07390383
P2RecruitingAdvanced Solid Tumour1102028-05-30
LBL-024 for Injection
NCT07331155
P2RecruitingAdvanced Solid Tumour1102028-12-26
LBL-034 for Injection
NCT06049290
P1/2RecruitingRelapsed/Refractory Multiple Myeloma3422029-09-20 (+35 mo)
LBL-024 for Injection
NCT07791758
P1/2RecruitingMetastatic Colorectal Carcinoma3692030-09-04
LBL-024 for Injection
NCT07720193
P3Not yet recruitingAdvanced Extrapulmonary Neuroendocrine Carcinoma2802030-12-22